MedTrace Logo

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT04999332 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-11-15

No results posted yet for this study

Summary

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

Conditions

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Effects of Chemotherapy
  • Toxicity Due to Chemotherapy

Interventions

DRUG

leucovorin, oxaliplatin, docetaxel, S-1

Perioperative chemotherapy with LOTS

Sponsors & Collaborators

  • TTY Biopharm

    collaborator INDUSTRY

  • Kaohsiung Veterans General Hospital.

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • China Medical University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    lead OTHER

Principal Investigators

  • Chia Jui Yen, M.D., Ph.D. · Department of Oncology, National Cheng Kung University Hospital

  • Yan Shen Shan, M.D., Ph.D. · Department of Surgery, National Cheng Kung University Hospital

  • I Shu Chen, M.D. · Department of General Surgery, Kaohsiung Veterans General Hospital

  • Li Yuan Bai, M.D., Ph.D. · Department of Hematology/Oncology, China Medical University Hospital

  • Ming Huang Chen, M.D., Ph.D. · Department of Oncology, Taipei Veterans General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999332 on ClinicalTrials.gov